Subgroup analysis revealed that increasing dietary ALA tends to elevate CRP concentration  in healthy subjects .
However , the null effect of ALA supplementation on other inflammatory markers was not changed in various subgroups , indicating that the results are stable .
Meta-regression results revealed a negative relationship between the effect size on CRP and its baseline concentration .
No significant publication bias was observed for all inflammatory markers as suggested by funnel plot and Begg ’s test .
Conclusion Our meta- analysis did not find any beneficial effect of ALA supplementation  on reducing inflammatory markers including TNF , IL-6 , CRP , sICAM-1 , and sVCAM-1 .
However , in healthy subjects  , ALA supplementation might increase CRP concentration
Purpose The aim of the current meta- analysis was to investigate the effect of increasing dietary ALA intake on the blood concentration of inflammatory markers including tumor necrosis factor ( TNF ) , interleukin 6 ( IL-6 ) , C-reactive protein ( CRP ) , soluble intercellular adhesion molecule-1 ( sICAM-1 ) , and soluble vascular cell adhesion molecule-1 ( sVCAM-1 )  in adults .
No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: The Alpha Omega Trial
Background heart failure is a major risk factor for cardiovascular mortality , for which n-3 fatty acids may have beneficial effects . We examined the effect of marine eicosapentaenoic acid ( EPA ) and docosahexaenoic acid ( DHA ) , and plant-derived alpha-linolenic acid ( ALA ) on N-Terminal-pro Brain Natriuretic Peptide ( NT-proBNP ) , a biomarker of heart failure . Methods we r and omly assigned 4837 post-myocardial infa rct ion patients , aged 60–80 years ( 82 % men ) , to margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA , 2 g/day ALA , EPA-DHA plus ALA , or placebo for 40 months . In a r and om selection of 639 patients , NT-proBNP was determined both at baseline and at the end of follow-up . NT-proBNP was loge-transformed and analysed by type of treatment using analysis of covariance adjusting for baseline NT-proNBP . Results patients consumed on average 19.8 g margarine/day , providing an additional amount of 238 mg/day EPA with 158 mg/day DHA , 1.98 g/day ALA , or both , in the active-treatment groups . In the placebo group , the geometric mean level NT-proBNP increased from 245 ng/l ( 95%-confidence interval [ CI ] : 207–290 ) to 294 ng/l ( 95%-CI : 244–352 ) after 40 months ( p = 0.001 ) . NT-proBNP levels were not affected by ALA ( + 8 % versus placebo ; 95%-CI : −8 % to + 25 % ; p = 0.34 ) , EPA-DHA ( + 2 % versus placebo ; 95%-CI : −14 % to + 18 % ; p = 0.78 ) , nor EPA-DHA plus ALA ( + 9 % versus placebo ; 95%-CI : −8 % to + 25 % ; p = 0.31 ) treatment . Conclusions supplementation with modest amounts of EPA-DHA , with or without ALA , did not have a significant effect on NT-proBNP levels in patients with a history of myocardial infa rct ion
Subgroup analysis revealed that increasing dietary ALA tends to elevate CRP concentration  in healthy subjects .
However , the null effect of ALA supplementation on other inflammatory markers was not changed in various subgroups , indicating that the results are stable .
Meta-regression results revealed a negative relationship between the effect size on CRP and its baseline concentration .
No significant publication bias was observed for all inflammatory markers as suggested by funnel plot and Begg ’s test .
Conclusion Our meta- analysis did not find any beneficial effect of ALA supplementation  on reducing inflammatory markers including TNF , IL-6 , CRP , sICAM-1 , and sVCAM-1 .
However , in healthy subjects  , ALA supplementation might increase CRP concentration
Purpose The aim of the current meta- analysis was to investigate the effect of increasing dietary ALA intake on the blood concentration of inflammatory markers including tumor necrosis factor ( TNF ) , interleukin 6 ( IL-6 ) , C-reactive protein ( CRP ) , soluble intercellular adhesion molecule-1 ( sICAM-1 ) , and soluble vascular cell adhesion molecule-1 ( sVCAM-1 )  in adults .